peptides and FAQ

Extend the separation window to four hours minimum. Oral peptides spend significantly more time in the GI tract competing for intestinal transporters, and zinc absorption from food or supplements occurs in the same duodenal and jejunal segments. The competitive binding window is longer because both compounds are present in the gut simultaneously rather than one being delivered systemically. Researchers using oral BPC-157 or similar formulations report best results when zinc is dosed at least five hours after the oral peptide.

Switch to glycinate or threonate. Citrate's laxative effect at doses above 300mg makes it impractical for timed protocols where you need reliable absorption without disruption. Glycinate is chelated to an amino acid, which buffers the osmotic load and eliminates the GI urgency. Threonate is more expensive but causes zero GI distress even at higher doses. It's the preferred form when tolerance is a limiting factor.

Dose before the higher-volume or higher-intensity session only. Administering GH secretagogues twice daily (once per session) risks receptor desensitisation and diminishing GH pulse magnitude within 48–72 hours, particularly with potent GHRPs like hexarelin. If both sessions are equally demanding, prioritise the evening session. Nocturnal GH pulse amplification supports overnight muscle protein synthesis more effectively than morning dosing. Alternatively, rotate peptide timing: dose before morning training on Monday/Wednesday/Friday, evening training on Tuesday/Thursday.

Skip the zinc dose and resume the normal schedule the next day. The interference is immediate but temporary. Zinc doesn't accumulate in a way that blocks future peptide doses. The peptide dose you just administered is already compromised (expect 60–70% absorption instead of 95%), but re-dosing won't fix it and may worsen GI distress. Resume your separated timing protocol the following day and monitor for reduced response markers over the next 48 hours.

Align red light timing with the peptide that has the shortest time to peak concentration (Tmax). If stacking BPC-157 (Tmax 45–60 minutes subcutaneous) with oral MK 677 (Tmax 120 minutes), dose both simultaneously and apply red light 50–60 minutes later. This captures BPC-157's full peak window and the rising phase of MK 677's GH secretion. For peptides with vastly different Tmax values (e.g., intranasal Cerebrolysin at 30 minutes and oral ibutamoren at 120 minutes), split into two separate red light sessions or prioritize the peptide with the primary research objective.

Pause AIP immediately and revert to a standard whole-foods baseline diet (no elimination restrictions) while continuing peptide dosing. Wait 4 weeks for dietary reintroduction effects to stabilize, then retest inflammatory markers. This creates a delayed but measurable peptide-only baseline. Once markers stabilize, reintroduce AIP elimination as a separate variable starting from the new baseline. You've lost 4–8 weeks of clean data, but you can still separate peptide and AIP effects moving forward.

You'll need a loading phase before peptide synergy becomes measurable. Take 5,000–10,000 IU daily for 4–8 weeks to raise serum 25-hydroxyvitamin D above 40 ng/mL, then retest before starting peptides. VDR expression scales with serum D3 status. Starting a peptide protocol with deficient baseline levels means receptor density is already compromised, and timing adjustments can't compensate for insufficient substrate. The peptide will still work but at 70–80% of potential bioavailability.

Neither complete rest nor peptides alone will resolve plantar fasciitis if you continue the same training load that caused it. The evidence-based approach: reduce weekly mileage by 30–40%, eliminate speed work temporarily, add eccentric calf strengthening (heel drops off a step), and begin BPC-157 (250–500mcg subcutaneously near the heel) twice weekly for 4–6 weeks. Research published in Foot & Ankle International shows that runners who modify training load while addressing tissue pathology see 60–70% symptom resolution within six weeks, compared to 20–30% for those who rest completely or continue unchanged.

Daily testosterone administration (20–30mg/day) maintains a stable androgen floor without the peak-trough variation of twice-weekly injections, but it also means there's never a 'low androgen window' for peptides to work optimally. The workaround: administer peptides at least eight hours after the daily testosterone dose and immediately before bed. This timing capitalizes on the nocturnal GH surge while the daily testosterone microdose is at its trough. Alternatively, consider switching to an every-other-day peptide protocol to create separation windows.

Proceed with the red light session but do not expect synergistic amplification for that day's peptide dose. Photobiomodulation alone still increases ATP synthesis, supports mitochondrial function, and provides baseline anti-inflammatory effects. Resume proper timing with the next peptide administration. Missing one session's synergy in a 4–12 week protocol does not negate cumulative benefits. Consistency over the protocol's full duration matters more than single-session optimization.

Shift your D3 dose to 30–60 minutes before peptide administration rather than taking it at an arbitrary time. If you currently take D3 in the morning and administer peptides in the evening, move your D3 dose to align with the peptide schedule. The synergy depends on temporal overlap between calcitriol signaling and peptide arrival. Same-day intake without timing coordination provides baseline D3 sufficiency but misses the receptor priming effect entirely.

Administer peptides 45–60 minutes before fasted training as usual. Fasted training amplifies endogenous GH release 2–3× fed-state levels due to low insulin and elevated catecholamines, but exogenous GH secretagogue timing still follows the same 60–90 minute peak window. The synergy is additive: fasted-state GH elevation + peptide-induced pulse creates a larger total GH exposure during the post-workout anabolic window. One caveat. Fasted training without post-workout protein intake eliminates the amino acid substrate required for GH-stimulated muscle protein synthesis, negating the timing advantage entirely. Consume 25–40g high-leucine protein within 60 minutes post-training.

Skip the dose entirely if fewer than four hours remain before your testosterone injection. Administering the peptide during the androgen peak wastes the compound and disrupts the protocol rhythm. Resume the regular schedule at the next planned administration time. Missing one peptide dose in a structured protocol has negligible impact on long-term results; stacking a missed dose with testosterone to 'catch up' negates both compounds and trains poor timing discipline.

You miss the protection window. Oral magnesium takes 45–90 minutes to reach peak plasma levels, and tissue diffusion into subcutaneous and interstitial compartments lags behind plasma by another 20–30 minutes. If you inject the peptide before magnesium has saturated the depot site, the peptide faces unprotected proteolytic degradation during its most vulnerable phase. The first 30 minutes post-injection when enzymatic activity is highest and peptide concentration is still elevated in a confined space.

Daily baseline supplementation helps, but it doesn't eliminate the need for timed dosing. Chronic magnesium supplementation raises average tissue levels from deficient to adequate, but it doesn't create the localized saturation spike that provides maximum proteolytic protection. Think of it this way: baseline supplementation gives you 15% protection; timed pre-injection dosing on top of that baseline gives you 28–35%. The effects are additive, not redundant.

No. BPC-157 has a short half-life (4–6 hours), meaning doubling the dose will spike plasma concentration temporarily but will not compensate for the missed recovery window. If you miss a Saturday evening post-long-run dose, the inflammatory cascade has already peaked and resolved by Monday. Skip the missed dose and resume the normal schedule. Doubling peptide doses increases the risk of injection site irritation and does not improve tissue repair outcomes. Consistency across training weeks matters more than individual dose timing.

Administer the peptide immediately and apply a second red light session 45–60 minutes later. Photobiomodulation increases ATP for 3–6 hours, but the peak effect occurs in the first 90 minutes post-exposure. If you dose the peptide two hours after red light, you're treating during ATP baseline return. A corrective second session realigns the temporal windows, though you've consumed two sessions' worth of device usage. Future sessions should follow the peptide-first sequence to avoid redundancy.

Dose zinc once daily at the time point furthest from all three peptide administrations. Typically mid-afternoon if peptides are dosed morning, midday, and evening. If the peptide schedule is tightly clustered (e.g., every 6 hours), consider splitting zinc into two smaller doses (7.5mg each) and placing them in the longest gaps between peptide doses. The total daily zinc remains 15mg, but absorption is distributed to avoid peak interference windows.

Yes, but timing matters. Vitamin C works best at low pH in the morning. Retinol works best at night. Peptides can go in either routine but separate them from strong vitamin C serums by a few minutes or use them at different times of day. A common approach: vitamin C morning, retinol evening, peptides morning and/or evening depending on formulation.